Results 11 to 20 of about 9,387 (173)
Клинический разбор в общей медицине, 2023 Langerhans cell histiocytosis is a rare proliferative disease of histiocyte-like cells, the peak incidence of which occurs in early childhood. Pulmonary Langerhans Cell Histiocytosis is one of the forms of this disease, but it usually affects young ...
Victor V. Fomin +4 more
doaj +2 more sources
Langerhans Cell Histiocytosis [PDF]
Advances in Anatomic Pathology, 1998 Langerhans cell histiocytosis (LCH) is a rare clonal disorder that consists of single or multiple mass lesions composed of cells with an abnormal Langerhans cell phenotype. Its etiology remains unknown, despite extensive searches for evidence of consistent cytogenetic abnormalities, gene rearrangements, or viral genomes.
K M, Herzog, R R, Tubbs
+11 more sources
Langerhans cell histiocytosis [PDF]
Blood, 2020 Abstract Langerhans cell histiocytosis (LCH) is caused by clonal expansion of myeloid precursors that differentiate into CD1a+/CD207+ cells in lesions that leads to a spectrum of organ involvement and dysfunction. The pathogenic cells are defined by constitutive activation of the MAPK signaling pathway.
Carl E. Allen, Carlos Rodriguez-Galindo
openaire +2 more sources
Clinical periodontal diagnosis
Periodontology 2000, EarlyView., 2023 Abstract Periodontal diseases include pathological conditions elicited by the presence of bacterial biofilms leading to a host response. In the diagnostic process, clinical signs such as bleeding on probing, development of periodontal pockets and gingival recessions, furcation involvement and presence of radiographic bone loss should be assessed prior ...
Giovanni E. Salvi +5 more
wiley +1 more source
Efficacy, safety, and relapse outcomes of MAPK inhibitors in pediatric Langerhans cell histiocytosis: A real-world study. [PDF]
Int J CancerWhat's new? Mitogen‐activated protein kinase (MAPK) inhibitors are promising treatments for pediatric Langerhans cell histiocytosis (LCH), a rare heterogeneous neoplasm that often affects multiple organ systems. Which MAPK inhibitors are most effective against LCH remains uncertain.
Tang X +5 more
europepmc +2 more sources
Langerhans Cell Histiocytosis [PDF]
Cancer Control, 2014 Langerhans cell histiocytosis (LCH) is a rare histiocytic disorder of unknown etiopathogenesis. Its clinical presentation is variable and ranges from isolated skin or bone disease to a life-threatening multisystem condition. LCH can occur at any age but is more frequent in the pediatric population. A neoplastic origin of this disease has been suggested
Giovannetti, Filippo +7 more
openaire +7 more sources
Journal of Indian Society of Periodontology, 2011 Langerhans cell histiocytosis (LCH) is a group of rare disorders histologically characterized by the proliferation of Langerhans cells. Multiple organs and systems may be involved by the disease. Typically, there is bone involvement and, less frequently, lesions may be found in the lungs, liver, lymph nodes, skin, and mucosa.
D R Aruna +3 more
openaire +3 more sources
Langerhans' Cell Histiocytosis
Dermatology Online Journal, 2002 Adult onset Langerhans cell histiocytosis is uncommon. A 29 year old man is presented who developed classic cutaneous disease with severe systemic involvement. He responded completely to a two month course of thalidomide.
Mortazavi, Hessein +3 more
openaire +4 more sources
Langerhans Cell Histiocytosis of the Skull
Ear, Nose & Throat Journal, 2021 This is a case of a pediatric male who presented with a postauricular mass and pain. Computed tomography and magnetic resonance imaging suggested a diagnosis of Langerhans cell histiocytosis.
Adrian A. Ong MD +2 more
doaj +1 more source
Journal of Contemporary Medicine, 2022 Scabies is an infestation caused by the Sarcoptes scabiei burrowing into the epidermis. Histopathologically scabies infestation may reveal Langerhans cell hyperplasia which might cause misdiagnosis of Langerhans cell histiocytosis in some cases.
Ayşe Esra Koku Aksu +5 more
doaj +1 more source